N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

A Methodological Study to Learn More About Kidney Function in Healthy People and in People With Reduced Kidney Function

Sponsor: Bayer • ClinicalTrials.gov ID: NCT07368712

Registry updated: 2026-10-14
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The main purpose of this study is to investigate how reliable a test assessing the renal functional reserve (RFR) and the maximum glomerular filtration rate (maxGFR) are. MaxGFR and RFR assessments are repeated twice at 1-month intervals. If precise, this test may improve the measure of kidney function and be useful in future studies for people with chronic kidney problems. To do this, the researchers will collect and analyze information about kidney function from up to 50 adults, including healthy people and people with stable kidney problems. Each person will come to the study center for a screening visit and then three study days, each about a month apart. On each study day, participants will have blood and urine samples taken before and after drinking a protein shake. The tests will measure things like creatinine, cystatin C, and other markers in the blood and urine to see how the kidneys are working. The study will also record basic health information, weight, blood pressure, and any medicines being taken. The study will last about 2 to 2.5 months for each participant.

Interventions

  • No investigational study intervention (Other)
    The study does not involve the administration of any study intervention, investigational medicinal product, or device. Participants will undergo blood collection and urine sampling both before and after consuming a high-protein meal.

Eligibility criteria

Inclusion Criteria: * Participant must be 18 to 75 years of age inclusive, at the time of signing the ICF. * Stable medical condition defined as no new drug or other treatment prescribed for a chronic condition within 60 days prior to Study Day 1. * Body weight between 50 and 100 kg. * Female Participants: A participant is eligible to participate if not pregnant or breastfeeding. If a urine test cannot be confirmed as negative at screening (e.g., an ambiguous result), the participant must be excluded from participation. Exclusion Criteria: * Recent surgical intervention within 60 days prior to Study Day 1. * New clinical diagnosis established within 60 days prior to Study Day 1. * New drug prescription within 60 days prior to Study Day 1. * Relevant change in severity of any medical condition within 60 days prior to Study Day 1, e.g. disease flare. * Known congenital amino acid metabolism disorders. * Severe hypersensitivity to milk products. * Known liver cirrhosis. * Regular use of non-steroidal anti-inflammatory drugs (NSAIDs). * Impaired kidney function with eGFR \<30 mL/min/1.73m2

Conditions

Acute Kidney Injury, Renal Insufficiency

Locations

  • Bayer AG - Occupational Health Services — Berlin, State of Berlin, Germany
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record